Women who develop infection during delivery hospitalization are at higher risk of being readmitted for ischaemic stroke within 30 days postpartum, especially those with no hypertensive disorders of pregnancy, a study reports.
Use of menopausal hormone therapy (MHT) was associated with a significantly increased risk of invasive breast cancer, which became progressively greater with longer duration of use, a meta-analysis of worldwide prospective epidemiological studies has shown.
Young Singaporean women are likely to get themselves immunized against human papillomavirus (HPV) with the motivation to protect their own health, positive information about the vaccine and parental encouragement, as reported in a recent qualitative study.
A Mediterranean-style diet may reduce the risk of gestational diabetes and weight gain in pregnant women with metabolic risk factors, but not the overall risk of maternal and offspring adverse outcomes, according to the ESTEEM* trial.
Use of a water-impermeable, friction-reducing barrier film (BF) may reduce skin toxicity (eg, radiation dermatitis, burning, and pruritus) on high-friction breast regions in women with breast cancer receiving post-lumpectomy adjuvant radiation therapy, according to a study.
Measuring the ratio of the soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) improves the accuracy of identifying pre-eclampsia without changing admission rates, according to the results of a trial.
Patients with HER2+ breast cancer with disease progression despite ≥2 lines of HER2-directed therapy may improve their progression-free survival (PFS) with the addition of neratinib than lapatinib to capecitabine, according to the phase III NALA* trial.
Infection with hepatitis B virus (HBV) does not appear to independently affect pregnancy outcomes, although it contributes to prolonged infertility, higher odds of secondary infertility, ovulatory disorders and reduced implantation rate, a study has found.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The addition of ezetimibe improves statin treatment in acute coronary syndrome (ACS) patients with dyslipidaemia and low eicosapentaenoic acid-to-arachidonic acid (EPA/AA) ratio, resulting in a lowered risk of cardiovascular events compared to monotherapy, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019) held in Paris, France.